Homepage Featured News
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
Presentations to highlight role of liquid biopsy tests and real-world data to identify biomarkers, predict patient response to therapy, and detect resistance mechanisms in late-stage cancers
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
Agreement will leverage GuardantINFORM real-world evidence platform to advance development efforts for core cancer indications
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
Only blood test that detects minimal residual disease in patients with solid tumors without need for tissue biopsy now available for three cancers impacting 6 million people in US annually1
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
Blood test provides simple way to test patients comprehensively for tumor alterations that drive selection of targeted therapies, now including ENHERTU
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
Guardant Health’s management is scheduled to participate in a fireside chat on Wednesday, August 10 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com.
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib treatment
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic strategies in lung cancer
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
First blood-only liquid biopsy test for molecular residual disease testing now covered for certain fee-for-service Medicare patients in US with stage II or III colorectal cancer
Steve E. Krognes Joins Guardant Health Board of Directors
Mr. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Therapeutics Inc., Gritstone bio, Inc. and RLS Global AB, and previously served on the board at Corvus Pharmaceuticals, Inc.
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
Guardant Health today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and its affiliates, giving the company full control over operations throughout the Asia, Middle East and Africa region.